AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease

NCT00396201 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Hodgkin's Disease

Interventions

DRUG: G-CSF Plus Plerixafor

Sponsor

Genzyme, a Sanofi Company